RT Journal Article
SR Electronic
T1 Resurgence of SARS-CoV-2 in India: Potential role of the B.1.617.2 (Delta) variant and delayed interventions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.23.21259405
DO 10.1101/2021.06.23.21259405
A1 Maxwell Salvatore
A1 Rupam Bhattacharyya
A1 Soumik Purkayastha
A1 Lauren Zimmermann
A1 Debashree Ray
A1 Aditi Hazra
A1 Michael Kleinsasser
A1 Thomas Mellan
A1 Charlie Whittaker
A1 Seth Flaxman
A1 Samir Bhatt
A1 Swapnil Mishra
A1 Bhramar Mukherjee
YR 2021
UL http://medrxiv.org/content/early/2021/06/30/2021.06.23.21259405.abstract
AB India has seen a surge of SARS-CoV-2 infections and deaths in early part of 2021, despite having controlled the epidemic during 2020. Building on a two-strain, semi-mechanistic model that synthesizes mortality and genomic data, we find evidence that altered epidemiological properties of B.1.617.2 (Delta) variant play an important role in this resurgence in India. Under all scenarios of immune evasion, we find an increased transmissibility advantage for B.1617.2 against all previously circulating strains. Using an extended SIR model accounting for reinfections and wanning immunity, we produce evidence in support of how early public interventions in March 2021 would have helped to control transmission in the country. We argue that enhanced genomic surveillance along with constant assessment of risk associated with increased transmission is critical for pandemic responsiveness.One Sentence Summary Altered epidemiological characteristics of B.1.617.2 and delayed public health interventions contributed to the resurgence of SARS-CoV-2 in India from February to May 2021.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was supported by internal funding from the University of Michigan School of Public Health and Michigan Institute of Data Science.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research uses publicly available, deidentified data and is IRB exempt.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe use data on reported infected cases and COVID-19-attributed deaths through May 31, 2021, for our descriptive analysis (Section 1) and May 15, 2021, for predictive modeling (Sections 2 and 3) from covid19india.org (14). Population data for India was obtained from Our World in Data (71). Genomic data was obtained from GISAID (49, 50). Analysis code are available at on the Center for Precision Health Data Science GitHub page: https://github.com/umich-cphds/covid_india_wave2. https://github.com/umich-cphds/covid_india_wave2 https://www.covid19india.org https://www.gisaid.org